Haemwill (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemwill is indicated for the management of bleeding disorders that involve deficiencies of Factor VIII and von Willebrand factor. It is used in clinical practice to replace missing clotting proteins and to help achieve hemostasis in affected individuals.

• Treatment of hemophilia A in patients with low or absent Factor VIII levels.
• Management of von Willebrand disease types 1, 2, and 3.
• Perioperative prophylaxis for surgical procedures in patients with these disorders.
• On-demand therapy for breakthrough bleeding episodes.
• Long‑term prophylactic regimens to reduce bleeding frequency.

Side effects of Haemwill may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Mild fever or chills during infusion.
• Headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Local infusion site reactions such as redness or swelling.
• Transient increase in blood pressure.

Serious

• Development of inhibitors (antibodies) against Factor VIII or von Willebrand factor.
• Severe allergic reactions, including anaphylaxis.
• Thromboembolic events such as deep vein thrombosis.
• Renal impairment or acute kidney injury.
• Disseminated intravascular coagulation (DIC).

Healthcare providers should consider several precautions when prescribing Haemwill to ensure safe and effective use.

• Assess patient history for previous inhibitor development or allergic reactions.
• Monitor for signs of thrombosis, especially in patients with risk factors.
• Evaluate renal and hepatic function prior to initiating therapy.
• Use caution in pregnant or breastfeeding individuals; limited data are available.
• Ensure proper aseptic technique to prevent contamination during intravenous administration.
• Educate patients on recognizing symptoms of serious adverse reactions and when to seek medical attention.

Haemwill may interact with other medications or substances that affect hemostasis or immune response.

Avoid

• Concurrent use of other clotting factor concentrates without medical supervision.
• Administration with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
• Use of investigational gene‑therapy agents targeting coagulation pathways.

Use with caution

• Antifibrinolytic agents such as tranexamic acid, which may enhance clot stability.
• Immunosuppressive therapies that could alter inhibitor formation.
• Concomitant anticoagulants (e.g., warfarin, direct oral anticoagulants) requiring careful monitoring of coagulation parameters.
• Vaccinations administered close to infusion times, as they may affect immune response.